Back to School: How biopharma can reboot drug development. Access exclusive analysis here

POTP starts melanoma Phase II

Point Therapeutics (POTP) began a Phase II trial of talabostat (PT-100) as a single

Read the full 140 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE